drugset / Trial / NCT01509144

EuroNeut41: Safety & Immunogenicity of Immunisations With HIV Vaccine

NCT01509144 ↗

Phase 1 Completed 48 enrolled PX'Therapeutics European Commission · collab
RandomizedParallel-groupTriple-blindPrevention

Summary

Objectives: * To assess the safety of three priming immunisations by nasal route followed by two booster immunisations by intramuscular route * To assess immunogenicity responses induced by the vaccine.

Timeline

Start
2012-01
Primary completion
2013-06
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator EN41-FPA2 Vaccine 20 ug Intranasal
Comparator EN41-FPA2 Vaccine 100 ug Intranasal
Comparator EN41-FPA2 Vaccine 200 ug Intranasal